SBIR TOPIC 081: ADJUVANT DEVELOPMENT FOR VACCINES AGAINST INFECTIOUS OR IMMUNE-MEDIATED DISEASES

SBIR 主题 081：针对传染性或免疫介导疾病的疫苗的佐剂开发

• 批准号: 10281989
• 负责人: PAUL GUYRE
• 金额: $ 60万
• 依托单位: CELDARA MEDICAL, LLC
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-01 至 2022-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10281989
• 关键词: Adjuvant; Antibody Response; Blood; Clinical; Contracts; Development; Disease; Epitopes; Evaluation; Goals; Ha antigen; Human; Human Resources; Immune; Immunity; Infection; Influenza; Mediating; National Institute of Allergy and Infectious Disease; New York; Program Development; Protein Secretion; Regulation; Safety; Small Business Innovation Research Grant; Support Contracts; Vaccination; Vaccine Adjuvant; Vaccines; Work; immunogenicity; influenza virus vaccine; influenzavirus; medical schools; novel vaccines; pandemic influenza; preclinical development; protective efficacy; scale up; seasonal influenza; vaccine development

This contract is part of the NIAID Adjuvant Development program, which supports the preclinical development of novel vaccine adjuvant candidates. The goal of this contract is to support the further development of the ASP-1 adjuvant within the context of a vaccine to protect against influenzas.

该合同是 NIAID 佐剂开发计划的一部分，该计划支持新型疫苗佐剂候选物的临床前开发。 该合同的目标是支持在预防流感的疫苗中进一步开发 ASP-1 佐剂。